Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

14 evidence topics · 15 sources

Summary: target population

The Breakthrough Therapy Designation covers ficerafusp alfa with pembrolizumab “for the first line (1L) treatment of patients with metastatic or with unresectable, recurrent (R/M) head and neck squamous cell carcinoma (HNSCC) whose tumors express programmed death-ligand 1 with combined positive score (CPS) ≥1, excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.” The pivotal FORTIFI-HN01 trial (NCT06788990) enrolls recurrent or metastatic HNSCC with a primary tumor in the “oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC)”; paranasal sinus and nasopharyngeal primaries are excluded. The EU trial record requires “documentation of HPV-negative disease per central testing performed if presenting with OPSCC”, and lists the development of an HPV DNA assay among the sponsor's delegated duties. HPV status is therefore established by testing only for oropharyngeal primaries; Bicara states that HPV testing is “typically only being conducted in tumors originating from the oropharynx”, and the College of American Pathologists recommends against routine HR-HPV testing of primary oral cavity, laryngeal, nasopharyngeal, and hypopharyngeal carcinomas for prognostic purposes. Participants must have “PD-L1 CPS ≥1”, which the EU record specifies as “PD-L1 immunohistochemistry [IHC] via 22C3” in participants eligible “to receive pembrolizumab as frontline monotherapy”. Other criteria are no prior systemic therapy in the recurrent or metastatic setting, systemic therapy for locoregionally advanced disease completed more than 6 months earlier, no prior anti-EGFR antibody outside radiosensitizing or multimodal treatment, no immune checkpoint inhibitor within 6 months, measurable disease by RECIST 1.1, ECOG performance status 0 or 1, and no higher risk of bleeding.

Summary: position relative to current first-line therapy

Ficerafusp alfa would be added to pembrolizumab in first-line treatment, the setting in which pembrolizumab monotherapy (CPS ≥1) and pembrolizumab with platinum and fluorouracil are FDA approved, offered by ASCO with a strong recommendation for CPS ≥1, and listed by NCCN as preferred first-line options. The intended population overlaps the pembrolizumab monotherapy label population, which requires CPS ≥1 by an FDA-authorized test. Hanna et al. state that the combination “could provide a chemotherapy-free regimen”. Bicara reports a “two-to-three-fold increase in median OS” relative to pembrolizumab monotherapy or pembrolizumab with chemotherapy, and states that “No head-to-head studies have been conducted, and cross-trial comparisons may not be reliable”. The available results for ficerafusp alfa are from a single-arm phase 1b trial; topline results of the FORTIFI-HN01 interim analysis are expected in mid-2027, with a potential U.S. launch in 2028.

Summary: anticipated use and care setting

Bicara estimates about 50,000 HPV-negative patients newly diagnosed each year in the United States, EU5, and Japan, about 18,000 of them in the United States, and states that 80% of recurrent or metastatic HNSCC is HPV-negative. In KEYNOTE-048, 85% of tumors had CPS ≥1; among U.S. real-world first-line pembrolizumab recipients with a CPS result (352 participants, 54.5% of the cohort), 83.8% had CPS ≥1. In a U.S. nationwide database drawn primarily from community practices, 32.7% of 2,207 participants with recurrent or metastatic HNSCC received PD-L1 testing before first-line therapy and 50.0% were never tested. In the phase 1b trial, ficerafusp alfa 1,500 mg was given intravenously on days 1, 8, and 15 of 21-day cycles with pembrolizumab 200 mg on day 1; the protocol specifies a 120-minute infusion, extendable to 4 hours, and observation with vital-sign monitoring for 2 hours after the first 2 doses. Bicara is developing a less frequent dosing regimen. Among U.S. real-world first-line pembrolizumab recipients, 583 (90.2%) were treated in community practices and 57 (8.8%) in academic practices.

Company estimate of the target population
PopulationCompany estimate
HPV-negative patients newly diagnosed each year in the United States, EU5, and Japan“~50K”
Of those, patients in the United States“~18K”